Moderna, Inc. (NASDAQ:MRNA) Position Increased by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC boosted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 26.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,504 shares of the company’s stock after purchasing an additional 6,339 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Moderna were worth $3,622,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Moderna by 15.1% during the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after buying an additional 5,129,800 shares during the last quarter. Wellington Management Group LLP grew its position in Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after acquiring an additional 1,614,460 shares in the last quarter. Capital World Investors increased its stake in shares of Moderna by 0.5% during the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock worth $388,743,000 after purchasing an additional 18,728 shares during the last quarter. Mawer Investment Management Ltd. raised its holdings in shares of Moderna by 6.7% during the 1st quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock valued at $204,230,000 after purchasing an additional 120,621 shares in the last quarter. Finally, Bellevue Group AG lifted its stake in shares of Moderna by 27.6% in the 4th quarter. Bellevue Group AG now owns 1,908,420 shares of the company’s stock valued at $189,792,000 after purchasing an additional 413,095 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In related news, CFO James M. Mock sold 689 shares of the company’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the transaction, the chief financial officer now directly owns 7,269 shares in the company, valued at $859,486.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO James M. Mock sold 689 shares of the company’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the sale, the chief financial officer now owns 7,269 shares of the company’s stock, valued at $859,486.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,158 shares of company stock worth $11,167,312. 15.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Leerink Partners lowered their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research report on Tuesday. William Blair reissued a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Piper Sandler reduced their target price on Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, September 13th. JPMorgan Chase & Co. cut Moderna from a “neutral” rating to an “underweight” rating and decreased their target price for the stock from $88.00 to $70.00 in a research report on Friday, September 13th. Finally, Jefferies Financial Group lowered shares of Moderna from a “buy” rating to a “hold” rating and dropped their price target for the company from $120.00 to $65.00 in a research report on Friday, September 13th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus target price of $100.44.

Moderna Price Performance

Shares of Moderna stock opened at $68.02 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The company has a market cap of $26.07 billion, a PE ratio of -4.34 and a beta of 1.68. The firm has a fifty day moving average price of $91.19 and a two-hundred day moving average price of $110.97. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter last year, the company earned ($3.62) earnings per share. The firm’s revenue was down 29.9% on a year-over-year basis. Analysts expect that Moderna, Inc. will post -9.52 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.